Effect of green tea on reward learning in healthy individuals: A randomized, double-blind, placebo-controlled pilot study

Nutrition Journal

Volumn 12, Issue 1, 2013, Pages

  Zhang, Qiangye ^a   Yang, Hongchao ^a   Wang, Jian ^a   Li, Aiwu ^a   Zhang, Wentong ^a   Cui, Xinhai ^a   Wang, Kelai ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Anhedonia; Depression; Green tea; Reward learning

Indexed keywords

GREEN TEA EXTRACT; PLACEBO;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FLUID INTAKE; HAMILTON SCALE; HUMAN; HUMAN EXPERIMENT; LEARNING; LONG TERM CARE; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NORMAL HUMAN; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; REWARD; TEA;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEARNING; MALE; PILOT PROJECTS; PLANT EXTRACTS; PREVALENCE; REWARD; TEA; YOUNG ADULT;

RODENTIA;

EID: 84879033187     PISSN: None     EISSN: 14752891     Source Type: Journal    
DOI: 10.1186/1475-2891-12-84     Document Type: Article

References (49)

1. L-Theanine reduces psychological and physiological stress responses. Kimura K, Ozeki M, Juneja LR, Ohira H, Biol Psychol 2007 74 1 39 45 10.1016/j.biopsycho.2006.06.006 16930802 (Pubitemid 44781395)
2. Anticancer and anti-inflammatory effects of cysteine metabolites of the green tea polyphenol, (-)-epigallocatechin-3-gallate. Lambert JD, Sang S, Hong J, Yang CS, J Agric Food Chem 2010 58 18 10016 10019 10.1021/jf102311t 20718469
3. Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. Frei B, Higdon JV, J Nutr 2003 133 10 3275S 3284S 14519826 (Pubitemid 37222256)
4. The dual action of epigallocatechin gallate (EGCG), the main constituent of green tea, against the deleterious effects of visible light and singlet oxygen-generating conditions as seen in yeast cells. Mitrica R, Dumitru I, Ruta LL, Ofiteru AM, Farcasanu IC, Molecules 2012 17 9 10355 10369 22932216
5. Green tea consumption is associated with depressive symptoms in the elderly. Niu K, Hozawa A, Kuriyama S, Ebihara S, Guo H, Nakaya N, Ohmori-Matsuda K, Takahashi H, Masamune Y, Asada M, et al. Am J Clin Nutr 2009 90 6 1615 1622 10.3945/ajcn.2009.28216 19828710
6. Green tea polyphenols produce antidepressant-like effects in adult mice. Zhu WL, Shi HS, Wei YM, Wang SJ, Sun CY, Ding ZB, Lu L, Pharmacol Res 2012 65 1 74 80 10.1016/j.phrs.2011.09.007 21964320
7. Symptom differences in major depression, dysthymia, panic disorder, and generalized anxiety disorder. Clark DA, Beck AT, Beck JS, Am J Psychiatry 1994 151 2 205 209 8296890 (Pubitemid 24053100)
8. Determinants of poor 1-year outcome of DSM-III-R major depression in the general population: results of the Netherlands mental health survey and incidence study (NEMESIS). Spijker J, Bijl RV, de Graaf R, Nolen WA, Acta Psychiatr Scand 2001 103 2 122 130 10.1034/j.1600-0447.2001.103002122.x 11167315 (Pubitemid 32147133)
9. Reduced reward learning predicts outcome in major depressive disorder. Vrieze E, Pizzagalli DA, Demyttenaere K, Hompes T, Sienaert P, de Boer P, Schmidt M, Claes S, Biol Psychiatry 2013 73 7 639 645 10.1016/j.biopsych.2012. 10.014 23228328
10. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Domschke K, Dannlowski U, Ohrmann P, Lawford B, Bauer J, Kugel H, Heindel W, Young R, Morris P, Arolt V, et al. Eur Neuropsychopharmacol 2008 18 10 751 759 10.1016/j.euroneuro.2008.05. 003 18579347
11. Affective neuroscience and psychophysiology: toward a synthesis. Davidson RJ, Psychophysiology 2003 40 5 655 665 10.1111/1469-8986.00067 14696720 (Pubitemid 37128031)
12. Reconsidering anhedonia in depression: lessons from translational neuroscience. Treadway MT, Zald DH, Neurosci Biobehav Rev 2011 35 3 537 555 10.1016/j.neubiorev.2010.06.006 20603146
13. Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Hasler G, Fromm S, Carlson PJ, Luckenbaugh DA, Waldeck T, Geraci M, Roiser JP, Neumeister A, Meyers N, Charney DS, et al. Arch Gen Psychiatry 2008 65 5 521 531 10.1001/archpsyc.65.5.521 18458204 (Pubitemid 351645048)
14. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. Knutson B, Adams CM, Fong GW, Hommer D, J Neurosci 2001 21 16 C159 11459880
15. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Tohen M, McDonnell DP, Case M, Kanba S, Ha K, Fang YR, Katagiri H, Gomez JC, Br J Psychiatry 2012 201 5 376 382 10.1192/bjp.bp.112.108357 22918966
16. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME, J Clin Psychiatry 2012 73 7 953 959 10.4088/JCP.11m07470 22901346
17. Bruneton J, Pharmacognosy, phytochemistry, medicinal plants Paris: Lavoisier Publ 2 1999
18. The relationship of coffee consumption with mortality. Lopez-Garcia E, van Dam RM, Li TY, Rodriguez-Artalejo F, Hu FB, Ann Intern Med 2008 148 12 904 914 10.7326/0003-4819-148-12-200806170-00003 18559841 (Pubitemid 351860822)
19. Habitual coffee consumption and risk of heart failure: a dose-response meta-analysis. Mostofsky E, Rice MS, Levitan EB, Mittleman MA, Circ Heart Fail 2012 5 4 401 405 10.1161/CIRCHEARTFAILURE.112.967299 22740040
20. Involvement of the endocannabinoid system in reward processing in the human brain. van Hell HH, Jager G, Bossong MG, Brouwer A, Jansma JM, Zuurman L, van Gerven J, Kahn RS, Ramsey NF, Psychopharmacology (Berl) 2012 219 4 981 990 10.1007/s00213-011-2428-8
21. The mesolimbic dopamine reward circuit in depression. Nestler EJ, Carlezon WA Jr, Biol Psychiatry 2006 59 12 1151 1159 10.1016/j.biopsych.2005.09. 018 16566899 (Pubitemid 44192421)
22. Real-time chemical responses in the nucleus accumbens differentiate rewarding and aversive stimuli. Roitman MF, Wheeler RA, Wightman RM, Carelli RM, Nat Neurosci 2008 11 12 1376 1377 10.1038/nn.2219 18978779
23. Anticipating instrumentally obtained and passively-received rewards: a factorial fMRI investigation. Bjork JM, Hommer DW, Behav Brain Res 2007 177 1 165 170 10.1016/j.bbr.2006.10.034 17140674 (Pubitemid 46054190)
24. Functional magnetic resonance imaging of reward prediction. Knutson B, Cooper JC, Curr Opin Neurol 2005 18 4 411 417 10.1097/01.wco.0000173463.24758.f6 16003117 (Pubitemid 41104804)
25. Reversal of LPS-induced immobility in mice by green tea polyphenols: possible COX-2 mechanism. Singal A, Tirkey N, Chopra K, Phytother Res 2004 18 9 723 728 10.1002/ptr.1520 15478205 (Pubitemid 39481691)
26. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN, Neuropsychopharmacology 2004 29 8 1538 1545 10.1038/sj.npp.1300471 15127079 (Pubitemid 38982247)
27. Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone-induced reduction of adult hippocampal neurogenesis. Mayer JL, Klumpers L, Maslam S, de Kloet ER, Joels M, Lucassen PJ, J Neuroendocrinol 2006 18 8 629 631 10.1111/j.1365-2826.2006.01455.x 16867184
28. Biphasic effects of morus alba leaves green tea extract on mice in chronic forced swimming model. Sattayasai J, Tiamkao S, Puapairoj P, Phytother Res 2008 22 4 487 492 10.1002/ptr.2346 18386251 (Pubitemid 351613413)
29. Green tea and coffee consumption is inversely associated with depressive symptoms in a Japanese working population. Pham NM, Nanri A, Kurotani K, Kuwahara K, Kume A, Sato M, Hayabuchi H, Mizoue T, Public Health Nutr 2013 1 9 http://www.ncbi.nlm.nih.gov/pubmed/?term=Green+tea+and+coffee+consumpt ion+is+inversely+associated+with+depressive+symptoms+in+a+Japanese+workin g+population
30. Diagnostic criteria for use in psychiatric research. Feighner JP, Robins E, Guze SB, Woodruff RA Jr, Winokur G, Munoz R, Arch Gen Psychiatry 1972 26 1 57 63 10.1001/archpsyc.1972.01750190059011 5009428
31. American Psychiatric Association, Diagnostic and statistical manual of mental disorders (Revised 4th ed.) Washington, DC: American Psychiatric Publishing 2000
32. World Health Organization, The ICD-10 Classification of Mental and Behavioral Diseases Geneva: WHO 1992
33. The dopamine synapse and the notion of pleasure centers in the brain. Wise R, Trends Neurosci 1980 3 5
34. Dopamine and depression: a review of recent evidence. I. Empir studies. Willner P, Brain Res 1983 287 3 211 224 6140979 (Pubitemid 14213761)
35. Dopamine and depression: a review of recent evidence. II. Theor approaches. Willner P, Brain Res 1983 287 3 225 236 6362771
36. Dopamine and depression: a review of recent evidence. III. The eff of antidepressant treat. Willner P, Brain Res 1983 287 3 237 246 6318882 (Pubitemid 14213763)
37. The role of dopamine in the pathophysiology of depression. Dunlop BW, Nemeroff CB, Arch Gen Psychiatry 2007 64 3 327 337 10.1001/archpsyc.64.3.327 17339521 (Pubitemid 46376789)
38. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. McCabe C, Mishor Z, Cowen PJ, Harmer CJ, Biol Psychiatry 2010 67 5 439 445 10.1016/j.biopsych.2009.11.001 20034615
39. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Price J, Cole V, Goodwin GM, Br J Psychiatry 2009 195 3 211 217 10.1192/bjp.bp.108.051110 19721109
40. Epigallocatethin-3-O-gallate counteracts caffeine-induced hyperactivity: evidence of dopaminergic blockade. Park KS, Eun JS, Kim HC, Moon DC, Hong JT, Oh KW, Behav Pharmacol 2010 21 5-6 572 575 20700049
41. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, reduces dichlorodiphenyl-trichloroethane (DDT)-induced cell death in dopaminergic SHSY-5Y cells. Tai KK, Truong DD, Neurosci Lett 2010 482 3 183 187 10.1016/j.neulet.2010.06.018 20542083
42. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, et al. J Neurosci 2005 25 38 8807 8814 10.1523/JNEUROSCI. 1521-05.2005 16177050 (Pubitemid 41362059)
43. Effects of epigallocatechin-3-gallate on behavioral impairments induced by psychological stress in rats. Chen WQ, Zhao XL, Wang DL, Li ST, Hou Y, Hong Y, Cheng YY, Exp Biol Med (Maywood) 2010 235 5 577 583 10.1258/ebm.2010.009329
44. Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): a growing concern. Javaid A, Bonkovsky HL, J Hepatol 2006 45 2 334 335 author reply 335-336 10.1016/j.jhep.2006.05.005 16793166
45. Acute liver failure induced by green tea extracts: case report and review of the literature. Molinari M, Watt KD, Kruszyna T, Nelson R, Walsh M, Huang WY, Nashan B, Peltekian K, Liver Transpl 2006 12 12 1892 1895 10.1002/lt.21021 17133573 (Pubitemid 44911818)
46. A case of hepatotoxicity caused by green tea. Federico A, Tiso A, Loguercio C, Free Radic Biol Med 2007 43 3 474 10.1016/j.freeradbiomed.2007.05. 010 17602963 (Pubitemid 46977635)
47. Plasma appearance and correlation between coffee and green tea metabolites in human subjects. Renouf M, Guy P, Marmet C, Longet K, Fraering AL, Moulin J, Barron D, Dionisi F, Cavin C, Steiling H, et al. Br J Nutr 2010 104 11 1635 1640 10.1017/S0007114510002709 20691128
48. Toxicity of green tea extracts and their constituents in rat hepatocytes in primary culture. Schmidt M, Schmitz HJ, Baumgart A, Guedon D, Netsch MI, Kreuter MH, Schmidlin CB, Schrenk D, Food Chem Toxicol 2005 43 2 307 314 10.1016/j.fct.2004.11.001 15621343 (Pubitemid 40037949)
49. Goitrogenic effects of green tea extract catechins by dietary administration in rats. Sakamoto Y, Mikuriya H, Tayama K, Takahashi H, Nagasawa A, Yano N, Yuzawa K, Ogata A, Aoki N, Arch Toxicol 2001 75 10 591 596 10.1007/s00204-001-0286-6 11808919 (Pubitemid 34025125)